Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed two 6-Ks on July 23, 2026, reporting the outcome of its 42nd Annual General Meeting. Shareholders appr | Jul 23, 2026 |
| IRD | 144 | neutral | 2/10 | Joseph K. Schachle, an officer of Opus Genetics, filed a Form 144 notice of intent to sell 4,644 shares of common stock, | Jul 23, 2026 |
| IRD | 144 | neutral | 2/10 | Opus Genetics (IRD) insider/officer Benjamin R. Yerxa filed a Form 144 notice to sell 7,429 shares for tax withholding r | Jul 23, 2026 |
| OPK | PRESS-RELEASE | neutral | 1/10 | OPKO Health, Inc. announced it will report its Q2 2026 results on July 27, 2026. | Jul 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K reporting a routine auditor change from Ernst & Young Associates LLP to Deloit | Jul 23, 2026 |
| OKYO | PRESS-RELEASE | neutral | 2/10 | OKYO Pharma issued a press release announcing that Non-Executive Director John Brancaccio purchased 5,000 ordinary share | Jul 23, 2026 |
| OKYO | 6-K | neutral | 2/10 | OKYO Pharma disclosed that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares at $1.48 per share on | Jul 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a Form 6-K on July 23, 2026, submitting an intimation (Exhibit 99.1) to the SEC. The exhibit content i | Jul 23, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma announced its Chief Medical Officer will participate in a bladder cancer panel at the BTIG Virtual Biotech | Jul 23, 2026 |
| CPHI | 424B5 | bearish | 6/10 | China Pharma Holdings is conducting a deeply dilutive offering of 2.5M shares at $2.00/share, a 75% discount to the $8.1 | Jul 23, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a 6-K on July 23, 2026, providing a link to the audio recording of its earnings call for the quarter e | Jul 23, 2026 |
| OKYO | 6-K | bullish | 4/10 | OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on Nasdaq at $1.54/share, a $23,100 open-market buy. | Jul 23, 2026 |
| UTHR | 8-K | neutral | 2/10 | United Therapeutics appointed Victor Dzau, M.D., former President of the National Academy of Medicine, to its Board of D | Jul 23, 2026 |
| WST | 8-K | bullish | 7/10 | West Pharmaceutical Services reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted | Jul 23, 2026 |
| IXHL | 8-K | neutral | 4/10 | Incannex Healthcare announced commencement of participant screening in its DReAMzz Phase 2 dose confirmation study of IH | Jul 23, 2026 |
| IKT | 8-K | bullish | 6/10 | Inhibikase Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its lead candidate IKT-001 for t | Jul 23, 2026 |
| CNTN | 8-K | bullish | 5/10 | Canton Strategic Holdings sold its clinical-stage biotech subsidiary Gravitas Life Sciences, LLC to a buyer affiliated w | Jul 23, 2026 |
| ESPR | 15-12G | neutral | 5/10 | Esperion Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g), effective immediately. Th | Jul 23, 2026 |
| GRML | 8-K | neutral | 4/10 | Greenland Mines Ltd adopted a limited-duration stockholder rights plan (poison pill) effective July 22, 2026, issuing on | Jul 23, 2026 |
| GRML | CLUSTER | bullish | 7/10 | Three insiders at Greenland Mines Ltd (GRML), including CFO Jeff LeBlanc, purchased $326K in open-market shares over a 7 | Jul 23, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jul 23, 2026 |
| IXHL | PRESS-RELEASE | bullish | 6/10 | Incannex Healthcare announced that participant screening has commenced in its DReAMzz Phase 2 dose confirmation study fo | Jul 23, 2026 |
| WST | PRESS-RELEASE | bullish | 7/10 | West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating co | Jul 23, 2026 |
| SER | PRESS-RELEASE | mixed | 5/10 | Serina Therapeutics completed enrollment in Cohort 1 of its Phase 1b registrational trial for SER-252 (Parkinson's disea | Jul 23, 2026 |
| SGMT | CLUSTER | neutral | 4/10 | Three Sagimet insiders, including the CEO, sold a combined $719K in open-market sales over a 7-day window. The CEO's $49 | Jul 23, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | A minor insider selling cluster at UTHR, CEO Rothblatt and EVP/GC Mahon sold a combined $521K in open-market transaction | Jul 23, 2026 |
| ARGX | PRESS-RELEASE | neutral | 5/10 | { "summary": "argenx reported Q2 2026 diluted EPS of $7.32, beating the $6.13 consensus by 19.4%, with product net sales | Jul 23, 2026 |
| LQDA | CLUSTER | bearish | 5/10 | A massive insider selling cluster at Liquidia Corp (LQDA) saw 10 insiders, including the CEO, CFO, and CCO, sell a total | Jul 22, 2026 |
| JSPR | 3 | neutral | 3/10 | Matthew E. Ros filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his position as Chie | Jul 22, 2026 |
| KROS | 8-K | neutral | 3/10 | CFO Keith Regnante resigned effective August 3, 2026, to pursue other opportunities. Corporate Controller Annita Tanini | Jul 22, 2026 |